Form 8-K - Current report:
SEC Accession No. 0001213900-21-001312
Filing Date
2021-01-11
Accepted
2021-01-11 07:00:25
Documents
12
Period of Report
2021-01-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea133041-8k_nektartherap.htm   iXBRL 8-K 34190
  Complete submission text file 0001213900-21-001312.txt   207719

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20210111.xsd EX-101.SCH 3207
3 XBRL LABEL FILE nktr-20210111_lab.xml EX-101.LAB 34582
4 XBRL PRESENTATION FILE nktr-20210111_pre.xml EX-101.PRE 22721
5 EXTRACTED XBRL INSTANCE DOCUMENT ea133041-8k_nektartherap_htm.xml XML 3501
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 21519068
SIC: 2834 Pharmaceutical Preparations